F500 Pharma & Biotech · Pharmaceuticals · Regulatory action
Eli Lilly
Headline
Nothing company-specific confirmed this pass on data privacy, but Lilly is the manufacturer whose product sits at the centre of the FTC PBM case documented in the Pharmacy Benefit Managers tab - insulin.
Not independently verified. Verification status: Unverified - heuristic first draft. Publish state: draft unverified.
Nothing company-specific confirmed this pass on data privacy, but Lilly is the manufacturer whose product sits at the centre of the FTC PBM case documented in the Pharmacy Benefit Managers tab - insulin. The finding that belongs on this row is the one the FTC alleged: manufacturers were pushed to compete on the size of the rebate off list price rather than on net price, which created a shared incentive to raise list prices that patients paying against list absorbed. Manufacturers were participants in that system, not bystanders to it, even where the FTC's action named the PBMs.
- Severity
- Evidence tierUnassigned
- Claims confirmed
- Last verified2026-08-04
Primary source. None recorded — Unverified - heuristic first draft.
Terms
Arbitration
Not independently confirmed this pass — standard binding arbitration + class action waiver expected.
Data sharing
Not independently confirmed this pass with a company-specific consumer data lawsuit beyond the shared industry findings below. SHARED FINDING ACROSS MANY PHARMA COMPANIES: (1) A 2024 breach at CENCORA (a major pharmaceutical distributor, documented separately in the Healthcare Providers tab of this tracker) exposed patient information — names, addresses, birthdates, health diagnoses, and prescriptions — for patients in programmes run for manufacturers that used Cencora/The Lash Group; Eli Lilly and Company is listed among the 42 customers whose information was involved in the class settlement, alongside Bayer, Genentech, AbbVie, Novartis, Regeneron, GSK and others (HIPAA Journal). (2) A SEPARATE 2026 proposed class action, Nash v. Tempus AI, Inc., No. 1:26-cv-01688 (N.D. Ill., filed Feb. 13, 2026), under Illinois' Genetic Information Privacy Act, alleges Tempus obtained Ambry Genetics customers' GENETIC data without written consent and shares data with drug makers; the complaint lists Eli Lilly among the more than 70 pharma companies with which Tempus signed data agreements. These are allegations against Tempus (Lilly is not a defendant), and the case's current status was not checked.
Fees and billing
Not itemized this pass.
Contacts
Privacy contact. Not recorded.
Legal notice. Not verified this pass. If publicly traded: SEC Form 10-K cover page gives the official corporate address; the Secretary of State business-entity search in the state of incorporation gives the registered agent, which must accept service. If private: the state registered agent is usually the only reliable route.
Mailing address. Not recorded.
Evidence
No claims have been itemized for this row yet.
No sources are on file for this row yet.
Source vault
Link status: Candidate - not yet fetched
| Document | Last fetch | |
|---|---|---|
| Privacy policy See Eli Lilly's own published privacy policy | Not fetched yet | NOT CONFIRMED |
| Terms of service See Eli Lilly's own published terms of service | Not fetched yet | NOT CONFIRMED |
| Website No URL recorded | Not fetched yet | — |
| Primary source No URL recorded Verification: Unverified - heuristic first draft | Not fetched yet | — |
Enforcement
No enforcement actions are linked to this row.
State statute
No HQ state on file, so no state statute applies by headquarters.